J&J-backed Rapport Therapeutics shares debut nearly 6% higher

Rapport Therapeutics

07/06/2024 16:15

June 7 (Reuters) - Shares of Rapport Therapeutics
 RAPP.O , backed by Johnson & Johnson's  JNJ.N  venture capital
arm, rose nearly 6% in their market debut on Friday, valuing the
early stage therapy developer at $636.8 million.

 (Reporting by Sriparna Roy and Mariam Sunny in Bengaluru;
Editing by Shilpi Majumdar)
 ((Sriparna.Roy@thomsonreuters.com;))